Group structure
9 companies in 4 countries
Loading…
9 companies in 4 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
24 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABLAVAR2440mg/10ml (244mg/ml) | 3660mg/15ml (244mg/ml) · Solution | Gadofosveset | United States | Not marketed | 2008 |
| CARDIOLITE1 mg / vial · Powder For Solution | Technetium (99m tc) sestamibi | Canada | Marketed | 1990 |
| DEFINITY13.04mg/2ml (6.52mg/ml) · Injectable | Perflutren | United States | Marketed | 2001 |
| DEFINITY150 mcl / ml · Suspension | Perflutren | Canada | Marketed | 2002 |
| DEFINITY RT13.04mg/2ml (6.52mg/ml) · Injectable | Perflutren | United States | Marketed | 2001 |
| Luminity | Perflutren | EU (EMA) | Authorised | 2006 |
| Luminity 150 microliter/ml oplossing voor dispersie voor injectie of infusieDispersie | Perflutren | Netherlands | Authorised | 2006 |
| LUMINITY 150 MICROLITROS/ML GAS Y DISOLVENTE PARA SOLUCIÓN PARA DISPERSIÓN INYECTABLE Y PARA PERFUSIÓN150 Microlitro · Solución inyectable y para perfusión | Perflutren | Spain | Authorised | 2006 |
| NEURACEQ18 1.4-135mCi/ML · Solution | Florbetaben f-18 | United States | Marketed | 2014 |
| Neuraceq | Florbetaben (18f) | EU (EMA) | Authorised | 2014 |
| NEURACEQ 300 MBq/ml solucion inyectable300 MBq · Solución inyectable | Florbetaben (18f) | Spain | Marketed | 2014 |
| NEUROLITE0.9 mg / vial · Kit, Powder For Solution | Bicisate | Canada | Marketed | 1997 |
| NEUROLITE 900 MICROGRAMOS EQUIPO DE REACTIVOS PARA PREPARACION RADIOFARMACEUTICA0,9 mg + 0,072 mg · Polvo y disolvente para solución inyectable | Bicisato dihidrocloruro, Estaño | Spain | Marketed | 1996 |
| QUADRAMET153 LEXIDRONAM PENTASODIUM 50mCi/ML · Injectable | Samarium sm-153 lexidronam pentasodium | United States | Not marketed | 1997 |
| TECHNELITE740 gbq / gen · Solution | Technetium (99m tc) pertechnetate | Canada | Marketed | 1996 |
| THALLOUS CHLORIDE TL 201201 2mCi/ML | 201 2mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Thallous tl-201 | United States | Not marketed | 1977 |
| XENON XE 133133 1.3-1.7 CI/AMP | 133 6.3mCi/ML · Injectable | Xenon xe | United States | Not marketed | 1974 |
| ABLAVAR244 mg / ml · Solution | Gadofosveset | Canada | Cancelled | 2010 |
| GALLIUM74 MBq / ML · Solution | Gallium (67 ga) citrate | Canada | Cancelled | 1987 |
| MIRALUMA1 mg / vial · Powder For Solution | Technetium (99m tc) sestamibi | Canada | Cancelled | |
| THALLIUM2 mci / ml · Solution | Thallium (201 tl) chloride | Canada | Cancelled | 1976 |
| THALLIUM1 mci / ml · Solution | Thallium (201 tl) chloride | Canada | Cancelled | |
| XENON20 mci / vial · Gas | Xenon xe | Canada | Cancelled | |
| XENON10 mci / vial · Gas | Xenon xe | Canada | Cancelled |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 11 | 4 | 7 | CompaniesAll medicines |
| United States | 7 | 7 | 0 | CompaniesAll medicines |
| Spain | 3 | 3 | 0 | CompaniesAll medicines |
| European Union (EMA) | 2 | 2 | 0 | CompaniesAll medicines |
| Netherlands | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, Colombia, France, Italy, Sweden, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vencidos; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Läkemedelsverket, Sweden, Förvaringstemperatur och hållbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Report an error or request removalCorrections from the company itself are welcome.
Keep Lantheus’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callWell-known pharmaceutical groups, each with all its companies.